One of the most important causes of anticancer treatment failure is the development of multidrug resistance (MDR). The main characteristics of tumor cells displaying the MDR phenomena are cross-resistance to structurally unrelated cytotoxic drugs having different mechanisms of action and the overexpression of the MDR1 gene, which encodes a transmembrane glycoprotein named Pglycoprotein (P-gp). This study evaluated whether bromocriptine, a D 2 dopaminergic receptor agonist, influenced anticancer drug cytotoxicity and P-gp activity in a P-gp-expressing cell line compared to a non-expressing subline. The K i values for P-gp of cyclosporine and verapamil were 1.09 and 540 µ µ µ µM, respectively, and that of bromocriptine was 6.52 µ µ µ µM in a calcein-AM efflux assay using porcine kidney epithelial LLC-PK1 and L-MDR1 cells, overexpressing human P-gp. Bromocriptine at 10 µ µ µ µM reduced the IC 50 of doxorubicin (DXR) in K562-DXR from 9000 to 270 ng/ml and that of vincristine (VCR) in K562-VCR from 700 to 0.30 ng/ml, whereas the IC 50 values of DXR and VCR in the K562 subline were only marginally affected by these drugs. Bromocriptine restored the anticancer effect of DXR, VCR, vinblastine, vinorelbine and etoposide on MDR-tumor cells overexpressing P-gp. These observations suggest that bromocriptine has the potential to reverse tumor MDR involving the efflux protein P-gp in the clinical situation.
One of the most important causes of anticancer treatment failure is the development of multidrug resistance (MDR) in the body. The main characteristics of tumor cells displaying the MDR phenomena are cross-resistance to structurally unrelated cytotoxic drugs having different mechanisms of action and the overexpression of the mdr-1 gene, mapping to chromosome 7 (q21-31), which encodes a transmembrane glycoprotein named P-glycoprotein (Pgp).
1-3) P-gp, which is a 170-to 180-kDa membrane glycoprotein, has been extensively investigated with regard to the MDR phenomenon in tumor cells. 4, 5) The sequence and domain organization of P-gp are characteristic of the ABC (ATP-binding cassette) superfamily of active transporters, which include the related MDR associated protein (MRP).
6) P-gp functions as an ATP-dependent drug-efflux pump, actively excreting a variety of structurally unrelated anticancer drugs, such as anthracyclines, vinca alkaloids, epipodophyllotoxin, actinomycin D, mitomycin C and taxol, from cells before the drugs can exert their cytotoxic effects, thus producing resistance. 7, 8) In contrast, MDR modulators, substrates capable of blocking P-gp-mediated drug efflux, have been suggested to reverse P-gp-mediated drug resistance, and to improve the outcome of cancer chemotherapy. MDR modulators include the antiarrhythmic verapamil and the immunosuppressant cyclosporine, and PSC 833 and MS 209 have been developed as second-generation MDR modulators. However, clinical application of these drugs is limited by side-effects and the possibility that they may inhibit other transporters which are not related to MDR. Bromocriptine ( Fig. 1 ) has previously been reported to inhibit the ATPase activity and the function of P-gp.
9) Bromocriptine is a hydrophobic polycyclic molecule, classically described as D 2 dopaminergic receptor agonist. Bromocriptine has been used clinically to treat hyperprolactinemia, acromegaly and Parkinson's disease for more two decades and has slight side-effects in clinical use. 10) However, there are no available data on the MDR-reversing effect of bromocriptine, and the effect of bromocriptine on anticancer agents, such as P-gp substrates, in acquired MDR cells has not been investigated.
Previously, we reported an assay system for evaluation of P-gp-mediated transcellular transport using human Pgp-overexpressing cells, L-MDR1 cells. 11, 12) Based on data from this assay system, we predicted that bromocriptine might be clinically effective, with weaker side-effects than cyclosporine and verapamil, for cancer chemotherapy and for overcoming P-gp-mediated drug interaction.
We report here interactions of bromocriptine in L-MDR1 and K562-DXR cells, in addition to the parental cell line LLC-PK1 and K562 cells, and the MDR-reversing effect of bromocriptine on human MDR-tumor cells. 14) The cells were maintained in a RPMI-1640 medium supplemented with 10% fetal bovine serum. All cells were grown under an atmosphere of 5% CO 2 -95% air at 37°C. Cellular influx and efflux assay To study the function of the P-gp pump on K562-DXR cells, rhodamine 123 or DXR was used in an efflux assay.
MATERIALS AND METHODS

Drugs and chemicals
12) Cells (5.0×10 5 ) were washed and resuspended in 1 ml of serum-free RPMI-1640. Cells were incubated with 1 µM rhodamine 123 or DXR and P-gp inhibitors for 1 h at 37°C. After 1 h, the cells were washed twice with serum-free medium to remove excess rhodamine 123, DXR or P-gp modulators, resuspended in 1 ml of serum-free medium, and recultured at 37°C for 2 h. After 2 h of culture, cells were washed and analyzed on FACScaliber by accumulating events in the FL1 (rhodamine 123) and FL2 (DXR) channel. To quantify the effect of inhibitor treatment on rhodamine 123 and DXR efflux from K562-DXR cells, we measured the shift of the histogram to the right as compared with the control (rhodamine 123 or DXR alone).
Calcein-AM efflux assay
A kinetic fluorometric assay 11, 15, 16) was used to study the interaction of bromocriptine with P-gp. For the calcein-AM efflux assay, L-MDR1 and LLC-PK1 cells were seeded on 96-well tissue culture plates at a cell density of 1×10 5 cells/well. Cells were cultured in 200 µl per well of Medium 199 supplemented with 10% fetal bovine serum, 1% benzylpenicillin and streptomycin in an atmosphere of 5% CO 2 -95% air at 37°C for 1 day. Cells were plated in 96-well tissue culture plates in Medium 199 containing various P-gp modulators. After 30-min incubation, calcein-AM was added to a final concentration of 1 µM and the plates were placed in a Fluoroscan Asent (Labsystems, Finland). Fluorescence was measured at 0 to 30 min with 485 nm excitation and 530 nm emission filters. The rate of calcein accumulation in the presence and absence of modulators was calculated by linear regression analysis using the Asent software (Labsystems). The inhibitory effect on P-gp was calculated based on the calcein fluorescence at 30 min by using the following equation
Inhibitory effect on P-gp (%) and the K i value for P-gp was calculated using a modified form of the Michaelis-Menten equation.
17)
Alamar Blue cytotoxicity assay To quantify the effects of bromocriptine on anticancer drug cytotoxicity, Alamar Blue was used in a semiautomated fluorometric assay. 12, 18) Alamar Blue is non-fluorescent substrate that is cleaved to a fluorescent product by living cells. This activity is dependent on the cell viability. The amount of fluorescence thus correlates with the number of living cells. Cells were harvested and plated at 5.0×10 3 cells/well in a volume of 80 µl in 96-well microtiter plates. Twenty microliter aliquots of drugs in the culture medium at the desired drug concentration were added and the cells were cultured for 48 h under the conditions described above. Ten microliter of Alamar Blue was added to each well of the plates, which were then incubated under the culture conditions for an additional 4 h. Measurement of fluorescence was done 
by a plate reader, Fluoroscan Asent (Labsystems), with excitation at 544 nm and emission at 590 nm. Statistical analysis Student's t test was used to evaluate the significance of differences. A P value of 0.05 or less was considered to be significant.
RESULTS
Effect of bromocriptine on the efflux of rhodamine 123 and DXR We measured rhodamine 123 and DXR efflux as a functional test to evaluate the effects of bromocriptine on the P-gp pump. As shown in Fig. 2A , rhodamine 123 was accumulated in K562 cells but not in K562-DXR cells, although the efflux of rhodamine 123 from K562-DXR cells could be blocked by bromocriptine at the concentration of 10 µM, and this effect was dose-dependent. However, it was difficult to examine the inhibitory effect of bromocriptine concentrations over 10 µM on P-gp because of its low solubility. The efflux of DXR was completely inhibited by only 1 µM bromocriptine (Fig. 2B ). Fig. 3 shows that the inhibitory effects of P-gp modulators were in the order; cyclosporine > bromocriptine > verapamil. Fig. 4 shows calcein-AM efflux in L-MDR1 cells in the presence of cyclosporine, verapamil and bromocriptine, which are potent P-gp modulators. The calcein fluorescence in L-MDR1 cells without drugs was significantly lower than that of LLC-PK1 cells, the parental cells.
Effect of bromocriptine on calcein-AM efflux in L-MDR1 cells
11) Cyclosporine, verapamil and bromocriptine significantly increased calcein fluorescence in L-MDR1 cells (P<0.05). These P-gp modulators did not affect calcein accumulation in LLC-PK1 cells (data not shown). Fig. 5 summarizes the effects of cyclosporine, bromocriptine and verapamil on the extent of calcein accumulation in L-MDR1 cells compared to LLC-PK1 cells. Inhibitory effect on P-gp modulators was calculated from the calcein fluorescence at 30 min, as described in "Materials and Methods." The inhibitory effects on P-gp were 75%, 58% and 10% at the concentration of 10 µM cyclosporine, bromocriptine and verapamil, respectively. Cyclosporine, bromocriptine and verapamil inhibited P-gp function with K i values of 1.09, 6.52 and 540 µM, respectively. In this analysis, bromocriptine inhibited P-gp activity with affinities in the order cyclosporine>bromocrip-tine>verapamil, the same order as that observed in flow cytometry analysis using rhodamine 123.
Effect of bromocriptine on MDR in human tumor cells
The K562 cell line was approximately 90 times as sensitive to DXR as K562-DXR, and 700 times as sensitive to VCR as K562-VCR. The IC 50 values for DXR and VCR were approximately 9000 and 700 ng/ml for K562-DXR and K562-VCR (Fig. 6) , respectively. Table I (10 µM) reduced IC 50 for DXR to 270 ng/ml for K562-DXR and that for VCR to 0.30 ng/ml for K562-VCR. On the other hand, bromocriptine had no effect on DXR and VCR cytotoxicity in K562, the parental line (data not shown). The MDR-reversing indexes were determined by dividing IC 50 of cells cultured without bromocriptine by IC 50 of the cells cultured with bromocriptine. Bromocriptine restored the anticancer effect of these drugs (DXR, VCR, vinblastine, vinorelbine and etoposide) on these MDR-tumor cells overexpressing P-gp. In particular, bromocriptine reversed the cytotoxic effect of vinca alkaloids (VCR, vinblastine and vinorelbine) on K562-DXR and K562-VCR by as much as 400 to 2000-fold. In contrast, in the study of A549 cells, which overexpress MRP, bromocriptine did not affect the cytotoxicity of any of the anticancer drugs we used.
DISCUSSION
Resistance to anticancer drug therapy is a major clinical problem leading to treatment failure. Therefore, investigations aimed at circumvention of intrinsic tumor-mediated drug resistance are warranted. The major cellular mechanism of drug resistance is overexpression of P-gp, which is an ATP-dependent drug efflux pump. In these experiments, we compared the ability of bromocriptine to inhibit P-gp function by using L-MDR1 cells transfected with human MDR1 cDNA, and MDR-tumor cells, which overexpress P-gp.
We demonstrated that K562-DXR cells were 90-fold less sensitive to DXR than K562 cells, and that rhodamine 123 was not accumulated in K562-DXR cells. Cyclosporine and verapamil, classical inhibitors of the P-gp pump, inhibited the efflux of rhodamine 123. Using this model, we investigated the ability of bromocriptine to alter the efflux of rhodamine 123 and DXR from P-gp-overexpressing K562-DXR cells. The order of affinity for P-gp was cyclosporine>bromocriptine>verapamil (Figs. 3 and 4) . As it was reported that MRP and lung resistance-related protein are not expressed on DXR-resistant K562 cells, 19) we consider that the inhibitory effects of the agents on rhodamine 123 and DXR efflux reflect the affinities of these drugs for P-gp. To access the effects of bromocriptine on P-gp activity, calcein-AM efflux was examined in LLC-PK1 and L-MDR1 cells and K i for P-gp inhibition was calculated from calcein accumulation. Cyclosporine, bromocriptine and verapamil inhibited P-gp function with K i values of 1.09, 6.52 and 540 µM, respectively (Fig. 5) . There was some difference in the inhibitory effect of bromocriptine on P-gp as assessed by flow cytometry analysis and by calcein-AM efflux assay. This difference might be caused by the differences in the methods used, and in the affinities of rhodamine 123 and calcein-AM for P-gp. These findings indicate that bromocriptine interacts with P-gp to inhibit the P-gp-mediated efflux of drugs.
Our results showed that bromocriptine blocked the Pgp-mediated drug resistance in K562-DXR and K562-VCR. We have obtained similar results with mouse MDRcancer cells, P388-DXR and P388-VCR. 20) On the other hand, in the case of A549, MRP-overexpressing cells, bromocriptine had little effect on the cytotoxicity of anticancer drugs. These data suggested that bromocriptine inhibits P-gp, but has little effect on MRP. Our preliminary data confirmed that the effect of bromocriptine on MRP-related efflux was slight, as judged from fluorescein accumulation assay in A549 cells. The results of this study demonstrated that bromocriptine inhibits the efflux of rhodamine 123 and calcein-AM from P-gp-overexpressing cells, and reverses P-gp-mediated drug resistance in MDR-tumor cells. As bromocriptine is better tolerated and causes fewer adverse reactions compared to other MDR modulators, especially verapamil, we believe that bromocriptine is a promising candidate for a new MDR-reversing agent. However, the plasma concentration of bromocriptine is expected to be very low in clinical use, 21) since bromocriptine is extensively metabolized by cytochrome P450 3A in the liver and about 96% of orally administered bromocriptine is converted to metabolites. 22, 23) To examine the feasibility of using bromocryptine in vivo, we administered vinorelbine in combination with bromocriptine to VCR-resistant P388 cellbearing CDF1 mice in a single dosing schedule. Preliminary data indicate that bromocriptine or cyclosporine increased life span by about 20%. Further work is in progress. We further found that a bromocriptine analog, mergocriptine, showed a P-gp-inhibitory effect, and a more detailed investigation of this analog is also warranted. 
